Cargando…

Dexamethasone in hyperleukocytic acute myeloid leukemia

Patients with acute myeloid leukemia and a high white blood cell count are at increased risk of early death and relapse. Because mediators of inflammation contribute to leukostasis and chemoresistance, dexamethasone added to chemotherapy could improve outcomes. This retrospective study evaluated the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bertoli, Sarah, Picard, Muriel, Bérard, Emilie, Griessinger, Emmanuel, Larrue, Clément, Mouchel, Pierre Luc, Vergez, François, Tavitian, Suzanne, Yon, Edwige, Ruiz, Jean, Delabesse, Eric, Luquet, Isabelle, Linares, Laetitia Karine, Saland, Estelle, Carroll, Martin, Danet-Desnoyers, Gwenn, Sarry, Audrey, Huguet, Françoise, Sarry, Jean Emmanuel, Récher, Christian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ferrata Storti Foundation 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6058767/ https://www.ncbi.nlm.nih.gov/pubmed/29519869 http://dx.doi.org/10.3324/haematol.2017.184267

Ejemplares similares

Genomic landscape of hyperleukocytic acute myeloid leukemia
por: Largeaud, Laetitia, et al.
Publicado: (2022)

Phenotypically-defined stages of leukemia arrest predict main driver mutations subgroups, and outcome in acute myeloid leukemia
por: Vergez, François, et al.
Publicado: (2022)

Vitamin C and D supplementation in acute myeloid leukemia
por: Mouchel, Pierre Luc, et al.
Publicado: (2023)

Outcome of patients aged 60‐75 years with newly diagnosed secondary acute myeloid leukemia: A single‐institution experience
por: Bertoli, Sarah, et al.
Publicado: (2019)

CD34(+)CD38(−)CD123(+) Leukemic Stem Cell Frequency Predicts Outcome in Older Acute Myeloid Leukemia Patients Treated by Intensive Chemotherapy but Not Hypomethylating Agents
por: Vergez, François, et al.
Publicado: (2020)

A robust and rapid xenograft model to assess efficacy of chemotherapeutic agents for human acute myeloid leukemia
por: Saland, E, et al.
Publicado: (2015)

Improved outcome for AML patients over the years 2000–2014
por: Bertoli, Sarah, et al.
Publicado: (2017)

Oncogenic KIT mutations induce STAT3-dependent autophagy to support cell proliferation in acute myeloid leukemia
por: Larrue, Clément, et al.
Publicado: (2019)

Prognostic impact of viral reactivations in acute myeloid leukemia patients undergoing allogeneic stem cell transplantation in first complete response
por: Guenounou, Sarah, et al.
Publicado: (2016)

Dendrogenin A Synergizes with Cytarabine to Kill Acute Myeloid Leukemia Cells In Vitro and In Vivo
por: Serhan, Nizar, et al.
Publicado: (2020)

Intermediate-dose cytarabine or standard-dose cytarabine plus single-dose anthracycline as post-remission therapy in older patients with acute myeloid leukemia: impact on health care resource consumption and outcomes
por: Galtier, Jean, et al.
Publicado: (2021)

CDC25A governs proliferation and differentiation of FLT3-ITD acute myeloid leukemia
por: Bertoli, Sarah, et al.
Publicado: (2015)

Therapy-related acute myeloid leukemia following treatment of lymphoid malignancies
por: Bertoli, Sarah, et al.
Publicado: (2016)

Outcome of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia before Second-Generation FLT3 Tyrosine Kinase Inhibitors: A Toulouse–Bordeaux DATAML Registry Study
por: Bertoli, Sarah, et al.
Publicado: (2020)

Dendrogenin A Enhances Anti-Leukemic Effect of Anthracycline in Acute Myeloid Leukemia
por: Mouchel, Pierre-Luc, et al.
Publicado: (2020)

Do AML patients with DNMT3A exon 23 mutations benefit from idarubicin as compared to daunorubicin? A single center experience
por: LaRochelle, Olivier, et al.
Publicado: (2011)

Azacitidine or intensive chemotherapy for older patients with secondary or therapy-related acute myeloid leukemia
por: Dumas, Pierre-Yves, et al.
Publicado: (2017)

Oxidative Phosphorylation Fueled by Fatty Acid Oxidation Sensitizes Leukemic Stem Cells to Cold
por: Griessinger, Emmanuel, et al.
Publicado: (2023)

Real-World Outcomes of Patients with Refractory or Relapsed FLT3-ITD Acute Myeloid Leukemia: A Toulouse-Bordeaux DATAML Registry Study
por: Dumas, Pierre-Yves, et al.
Publicado: (2020)

SHED-Dependent Oncogenic Signaling of the PEAK3 Pseudo-Kinase
por: Ounoughene, Youcef, et al.
Publicado: (2021)

Isocitrate dehydrogenase 1 mutations prime the all-trans retinoic acid myeloid differentiation pathway in acute myeloid leukemia
por: Boutzen, Héléna, et al.
Publicado: (2016)

Adrenomedullin-CALCRL axis controls relapse-initiating drug tolerant acute myeloid leukemia cells
por: Larrue, Clément, et al.
Publicado: (2021)

Oncogenic FLT3-ITD supports autophagy via ATF4 in acute myeloid leukemia
por: Heydt, Q, et al.
Publicado: (2018)

Autophagy regulates fatty acid availability for oxidative phosphorylation through mitochondria-endoplasmic reticulum contact sites
por: Bosc, Claudie, et al.
Publicado: (2020)

CD36 Drives Metastasis and Relapse in Acute Myeloid Leukemia
por: Farge, Thomas, et al.
Publicado: (2023)

Inhibition of the proteasome and proteaphagy enhances apoptosis in FLT3‐ITD‐driven acute myeloid leukemia
por: Lopez‐Reyes, Rosa G., et al.
Publicado: (2020)

Stable Isotope Labeling Highlights Enhanced Fatty Acid and Lipid Metabolism in Human Acute Myeloid Leukemia
por: Stuani, Lucille, et al.
Publicado: (2018)

Signaling mechanisms that regulate ex vivo survival of human acute myeloid leukemia initiating cells
por: Bhavanasi, Dheeraj, et al.
Publicado: (2017)

Impact of TP53 mutations in acute myeloid leukemia patients treated with azacitidine
por: Bories, Pierre, et al.
Publicado: (2020)

Inhibition of ubiquitin-specific protease 7 sensitizes acute myeloid leukemia to chemotherapy
por: Cartel, Maëlle, et al.
Publicado: (2020)

A case of cup‐like blasts associated with B‐lymphoblastic leukemia without NPM1 and FLT3 internal tandem duplication mutations
por: Rieu, Jean‐Baptiste, et al.
Publicado: (2020)

Targeting PP2A-dependent autophagy enhances sensitivity to ruxolitinib in JAK2(V617F) myeloproliferative neoplasms
por: Courdy, Charly, et al.
Publicado: (2023)

Exploiting metabolic vulnerabilities for personalized therapy in acute myeloid leukemia
por: Stuani, Lucille, et al.
Publicado: (2019)

Bcl-2 protein family expression pattern determines synergistic pro-apoptotic effects of BH3 mimetics with hemisynthetic cardiac glycoside UNBS1450 in acute myeloid leukemia
por: Cerella, C, et al.
Publicado: (2017)

Are social inequalities in acute myeloid leukemia survival explained by differences in treatment utilization? Results from a French longitudinal observational study among older patients
por: Berger, Eloïse, et al.
Publicado: (2019)

Dendrogenin A drives LXR to trigger lethal autophagy in cancers
por: Segala, Gregory, et al.
Publicado: (2017)

Multiple Severe Toxicities of L-Asparaginase and Their Innovative Management during Induction Therapy of Acute Lymphoblastic Leukemia in an Adult Patient
por: Beziat, Guillaume, et al.
Publicado: (2019)

Correction: Replication Study: Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia
por: Shan, Xiaochuan, et al.
Publicado: (2018)

Replication Study: Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia
por: Shan, Xiaochuan, et al.
Publicado: (2017)

Hyperleukocytic Acute Leukemia Circulating Exosomes Regulate HSCs and BM-MSCs
por: Yang, Yanmei, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_e94qb3801rdcqpllu9ne9mjnvf